Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purdue Palladone Risk Management Documents Requested By House Cmte.

Executive Summary

Purdue Pharma will submit documents relating to risk management for its pending pain therapy Palladone to the House Energy & Commerce Committee

You may also be interested in...



Purdue Palladone Phased Launch To Begin In First Half 2005

Purdue is planning a phased launch of Palladone that includes an initial year and a half of detailing to pain specialists and other experienced opioid prescribers only, beginning in the first half of 2005

Purdue Palladone Phased Launch To Begin In First Half 2005

Purdue is planning a phased launch of Palladone that includes an initial year and a half of detailing to pain specialists and other experienced opioid prescribers only, beginning in the first half of 2005

Congress’ Oxycontin concerns continue

Reps. Frank Wolf (R-Va), Jim Greenwood (R- Pa), Henry Bonilla (R-Texas) and Harold Rogers (R- Ky) meet with FDA Commissioner McClellan April 3 to discuss abuse of Purdue's OxyContin (oxycodone). Wolf sent a letter to HHS Secretary Thompson March 28 asking that OxyContin treatment be limited to patients with severe pain. The House Energy & Commerce committee is investigating OxyContin and Purdue's Palladone, a pain therapy pending at FDA (1"The Pink Sheet" March 3, p. 33)...

Related Content

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel